Success Metrics

Clinical Success Rate
75.8%

Based on 25 completed trials

Completion Rate
76%(25/33)
Active Trials
21(30%)
Results Posted
68%(17 trials)
Terminated
8(11%)

Phase Distribution

Ph phase_4
1
1%
Ph early_phase_1
1
1%
Ph not_applicable
1
1%
Ph phase_1
18
26%
Ph phase_3
11
16%
Ph phase_2
37
53%

Phase Distribution

19

Early Stage

37

Mid Stage

12

Late Stage

Phase Distribution69 total trials
Early Phase 1First-in-human
1(1.4%)
Phase 1Safety & dosage
18(26.1%)
Phase 2Efficacy & side effects
37(53.6%)
Phase 3Large-scale testing
11(15.9%)
Phase 4Post-market surveillance
1(1.4%)
N/ANon-phased studies
1(1.4%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

73.5%

25 of 34 finished

Non-Completion Rate

26.5%

9 ended early

Currently Active

21

trials recruiting

Total Trials

70

all time

Status Distribution
Active(25)
Completed(25)
Terminated(9)
Other(11)

Detailed Status

Completed25
Recruiting18
unknown11
Terminated8
Not yet recruiting4
Active, not recruiting3

Development Timeline

Analytics

Development Status

Total Trials
70
Active
21
Success Rate
75.8%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (1.4%)
Phase 118 (26.1%)
Phase 237 (53.6%)
Phase 311 (15.9%)
Phase 41 (1.4%)
N/A1 (1.4%)

Trials by Status

unknown1116%
withdrawn11%
not_yet_recruiting46%
completed2536%
recruiting1826%
active_not_recruiting34%
terminated811%

Recent Activity

Clinical Trials (70)

Showing 20 of 70 trialsScroll for more
NCT07318389Early Phase 1

ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer

Not Yet Recruiting
NCT07221149Phase 2

A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)

Recruiting
NCT03781323Phase 2

Neoadjuvant FOLFOX Therapy With Short Course Radiation and Active Surveillance in Locally Advanced Rectal Cancer

Active Not Recruiting
NCT07622017Phase 2

KORTUC (KRC-01) Plus Radiotherapy for Organ Preservation in Rectal Cancer

Not Yet Recruiting
NCT07284849Phase 3

A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

Recruiting
NCT07221357Phase 2

A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

Recruiting
NCT04929223Phase 1

A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)

Recruiting
NCT04068610Phase 1

COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC

Active Not Recruiting
NCT05702229Phase 2

Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Recruiting
NCT00959647Phase 2

A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study

Completed
NCT06663319Phase 1

A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers

Recruiting
NCT06179160Phase 1

A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

Recruiting
NCT07562490Phase 2

A Randomized Controlled Trial of Plasma ctDNA Methylation-Guided Adjuvant Chemotherapy Decision-Making in High-Risk Stage III (T4N+ or T1-3N2) Colorectal Cancer

Recruiting
NCT06625775Phase 1

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

Recruiting
NCT02359968Phase 2

PReoperative Chemoradiation (Paclitaxel-carboplatin or FOLFOX) for Resectable Esophageal and Junctional Cancer

Completed
NCT04808323Phase 1

MRI-Guided Adaptive Radiation Therapy for Organ Preservation in Rectal Cancer

Recruiting
NCT05733689Phase 1

Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)

Recruiting
NCT07323576Phase 2

A Study to Evaluate the Efficacy and Safety of Inavolisib When Administered in Combination With Bevacizumab and FOLFOX or FOLFIRI as First Line Therapy in Participants With Colorectal Cancer

Withdrawn
NCT05855200Phase 3

Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

Recruiting
NCT06106308Phase 2

Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation

Active Not Recruiting

Drug Details

Intervention Type
DRUG
Total Trials
70